AMRZ

Amrize is a newly-independent (spun from Holcim) North American building-solutions company with genuinely high-quality financials but a maturing, cyclical growth profile. The balance sheet is a standout: liabilities/equity of just 0.83x, equity up 33.7% YoY to $13.3B (largely separation-related recapitalization), $1.92B cash (+21.3%), and $2.21B operating cash flow against $788M capex — roughly $1.4B of free cash flow funding three 2025 acquisitions and shareholder returns. Management explicitly frames a disciplined capital-allocation playbook of bolt-on M&A in fragmented building-materials markets, and R&R (43% of revenue) lends some demand stability versus pure new-construction cyclicals.

The problem is that the operating trend is going the wrong way at a premium price. FY2025 revenue grew only 0.9% to $11.8B, and profitability fell across the board: operating income -13.2%, net income and diluted EPS -7.0%, Adjusted EBITDA margin compressed from 27.2% to 25.5%, and net margin slipped from 10.9% to 10.0%. ROE is a modest 8.9%. So this is a low-single-digit top-line grower with deteriorating margins and middling returns on capital — yet the stock trades at 25.9x earnings and 2.6x sales, a multiple that implies durable growth the recent numbers don't show. For a weather-/cycle-exposed cement and building-envelope business, that is full.